Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11890270-B2

Patent

Publication Date

2024-02-06

Expiration Date


Abstract

Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.

Core Innovation

The invention relates to crystalline polymorphic forms of ST-246, including polymorph Form I of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-benzamide, as well as additional crystalline Forms II, III, IV, V, and VI. Form I is characterized by an X-ray powder diffraction pattern with characteristic peaks at defined reflection angles (2θ). The polymorphs are further characterized using XRPD and FTIR.

The patent addresses moisture sensitivity and stability differences among ST-246 polymorphs, including conversion of certain forms under humid conditions. It states that Form I is thermodynamically most stable and non-hygroscopic, whereas other forms can be moisture-unstable and may convert, including that Forms II/IV can be anhydrates and Form V can be a hemihydrate.

The disclosed work includes purity and formulation-relevant performance attributes for Form I, including purity thresholds for isolated forms and particle-size-dependent behavior for micronized Form I. It reports dissolution profiles for micronized Form I in oral capsules with D90-dependent behavior, and provides antiviral testing and pharmacokinetic comparisons between Form I and Form V.

Claims Coverage

The partial claims provided include two independent claims. Across both claims, the inventive coverage centers on using ST-246 polymorph Form I defined by a specific XRPD peak set.

Treating Orthopoxvirus infections using XRPD-defined Form I ST-246

A method of treating Orthopoxvirus infections by administering a therapeutically effective amount of a polymorph Form I of ST-246, wherein Form I shows an X-ray powder diffraction pattern having characteristic peaks at specified reflection angles (2θ).

Treating eczema vaccinatum using XRPD-defined Form I ST-246

A method of treating eczema vaccinatum by administering a therapeutically effective amount of a polymorph Form I of ST-246, wherein Form I shows an X-ray powder diffraction pattern having characteristic peaks at specified reflection angles (2θ).

The claim set, as provided, requires administration of a therapeutically effective amount of ST-246 polymorph Form I identified by a characteristic XRPD peak list, covering treatment of Orthopoxvirus infections and treatment of eczema vaccinatum.

Stated Advantages

Form I is stated to be thermodynamically most stable and non-hygroscopic.

Form I is described as more stable relative to other polymorphs that can be moisture-unstable and convert under humid conditions.

The disclosed formulations/reporting indicate dissolution behavior of micronized Form I in oral capsules with D90-dependent dissolution profiles.

Documented Applications

Treating Orthopoxvirus infections by administering a therapeutically effective amount of polymorph Form I of ST-246.

Treating eczema vaccinatum by administering a therapeutically effective amount of polymorph Form I of ST-246.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.